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ÖSSZEFOGLALÁS 
A farmakovigilancia változik, ma már nemcsak egy tudomány, mely passzívan várja és felismeri a 
nemkívánatos hatásokat, hanem aktívan előrelátóan keresi és kezeli a kockázatokat. A 
biotechnológiával készült gyógyszerek farmakovigilanciája a hagyományos kismolekulájú 
gyógyszerek minden nehézségével foglalkozik, és ezen felül figyelembe veszi azok speciális 
sajátosságait, köztük az immunogenitást.  
A biotechnológiával készült gyógyszerek nemkívánatos gyógyszerhatásairól az amerikai FDA 
Medwatch Programjában végeztek kutatást, amely a monoklonális antitestekre adott biztonságossági 
riasztásokra fókuszált. A Medwatch biztonságossági riasztásokhoz a Kaplan-Meier féle időanalízist 
alkalmaztam, ahol az idő a biztonságossági riasztáshoz az eseményig eltelt időt jelenti, ebben az 
esetben a „túlélést”.  
A kutatás eredményei azt mutatják, hogy a nemkívánatos gyógyszerhatások bizonyos fajta előrejelzése 
lehetséges a megfigyelt forgalomba hozatal előtti klinikai és nem-klinikai adatok alapján. A már 
megfigyelt nemkívánatos gyógyszerhatásokon kívül, egy nagyobb százalék előre jelezhető a 
gyógyszer szerkezete és a gyógyszer célpontja alapján (a gyógyszer hatásmechanizmusa és lehetséges 
nemkívánatos hatások). Az in vitro és in vivo prediktív tesztek kiszélesítése és ezek rutin klinikai 
használata hozzájárulhat a további kiszámíthatósági vizsgálatokhoz.  
A Kaplan-Meier analízis eredménye alapján, egy kockázatkezelési terv segíthet a biztonságossági 
kockázat korai felismerésében. Egy biztonságossági kockázat felismeréséig eltelt idő 
közegészségügyileg rendkívül fontos. A biztonsági kockázatok korai felismerése csökkenti a 
nemkívánatos gyógyszerhatások által okozott morbiditást és mortalitást, ezáltal számos előnnyel jár az 
egészségügynek.  
A nemkívánatos gyógyszerhatások előrejelzése különösen fontos magas rizikójú esetekben, ahol a 
várható előny szintén magas. Egy nemkívánatos gyógyszerhatás újbóli megismétlődése (rechallenge) 
egy jó példa arra, amikor az előny nem indokolja a kockázatot. A megismétlődés fontos minden 
gyógyszeres terápiában és terápiás kockázatkezelésben, azonban a biotechnológiával készült 
gyógyszereknél kialakult immunológiai nemkívánatos gyógyszerhatások esetében az újbóli 
megismétlődésnek sajátos kockázatjósló funkciói vannak. Minden egyes jelentős nemkívánatos 
hatásnak, mely potenciálisan a kezelés megszakításához vezet, van egy reakció specifikus kiújulási 
algoritmusa. Ebben az esetben egy olyan mintán alapuló algoritmus alkalmazását javasolom, amelyet 
minden egyes magas-kockázatú, magas-előnyű esethez igazítani kell. 
        
 
 
1 SUMMARY  
Pharmacovigilance is changing. It is no longer a passive discipline of awaiting and detecting 
adverse reactions, but active in predicting and managing risks. Pharmacovigilance of 
biopharmaceuticals deals with all the complexities of conventional small molecule drugs, and 
on top of that, takes into account its own specificities. Most notably, this is immunogenicity. 
For biopharmaceuticals the task is, therefore, multiple-fold more complex.  
Medical product database search for adverse drug reactions to biopharmaceuticals was 
performed on the US FDA Safety Information and Adverse Event Reporting Program (FDA 
Medwatch). The search focused on safety alerts for monoclonal antibody therapeutics. Kaplan 
Meier analysis of time to Medwatch safety alert was also applied, in which the time to safety 
alert was used as time to event i.e. “survival”. 
The findings in this work indicate that a certain level of prediction of adverse drug reactions 
(ADRs) is possible based on observed pre-marketing clinical and non-clinical data. In 
addition to the actually observed ADRs, a large percentage can be predicted based on drug 
structure and the drug target (i.e. mechanism of action and potential adverse reaction). 
Expanding the spectrum of in vitro and in vivo predictive tests and their application in routine 
clinical use could contribute further to predictability assessment. 
As demonstrated by the Kaplan-Meier analysis, risk management planning may lead to earlier 
detection of safety concerns. Time to detection of an important safety finding is of utmost 
importance to public health. Earlier detection of safety concerns leads to decreased morbidity 
and mortality due ADRs and hence a range of benefits to healthcare. 
Predicting ADRs is particularly important in high-risk situations in which the expected benefit 
is also high. Rechallenge following an ADR is such an example in which the benefit may, or 
may not, justify the risk. Rechallenge is of importance in all pharmacotherapy and therapeutic 
risk management. However, in immunological ADRs to biotherapeutics, rechallenge has 
particular risk-predictive features. Each significant adverse reaction potentially leading to 
treatment discontinuation should have a reaction-specific rechallenge algorithm. A sample 
generic algorithm is proposed in this thesis which should be adapted to each particular high-
risk high-benefit situation. 
 
 
        
2 OBJECTIVES  
The overall objective of this thesis is to identify and assess the factors determining the safety 
of biopharmaceuticals, taking into account all available non-clinical and clinical methods for 
evaluation. Immunogenicity is the most specific safety concern of biopharmaceuticals and 
therefore the focus of this thesis.  
 The specific primary objective is to assess to what extent serious ADRs are predictable 
and to identify the available methods for reliable evaluation of immunological adverse 
reactions.  
 Analysis of time to detection of ADR is also regarded as an individual objective, since 
early detection is of major importance for public health. 
 Rechallenge of patients who developed an immune-mediated ADR is given special 
attention as a secondary objective. It is of particular importance for 
biopharmaceuticals as it may lead to a more severe reaction following subsequent 
administration. 
The starting point is purely scientific evaluation of predictability based on the available 
literature sources including regulatory databases and scientific publications. However, 
regulatory aspects of benefit-risk assessment and risk management planning within the 
pharmaceutical development and product life cycle management are considered. 
 
 
 
 
        
 
3 METHODS 
Methods applied were twofold: The initial step consisted of regulatory authority medical 
product database search for US FDA Medwatch safety alert for adverse reactions to 
therapeutic monoclonal antibodies (mAbs). The second step was Kaplan-Meier analysis of 
time alert, based on the data collected as part of the initial step.  
3.1 Regulatory authority medical product database search  
Medwatch safety alerts for mAbs were taken as search trigger.  Adverse reactions were cross-
checked with the initial product label at the time of approval.  
Alerts were assigned to one of the two categories: 
 Observed:  When increased frequency, severity, or other new properties were reported 
for essentially similar previously identified suspected adverse reactions.  
 Not observed: Reactions not described in the product label. It does not refer to events 
which may have been suspected based on mechanism of action or chemical structure. 
This novel definition is based on objective clinical findings. It does not account for 
pharmacological-toxicological assessment of what may have been hypothesized.   
Summary statistics were performed using Microsoft Excel. 
3.2 Kaplan-Meier analysis 
The Kaplan-Meier estimate is the simplest way of computing the survival over time in spite of 
difficulties associated with subjects or situations. It involves computing of probabilities of 
occurrence of event at a certain point of time and multiplying these successive probabilities 
by any earlier computed probabilities to get the final estimate. The analysis uses time to event, 
commonly referred to as “survival”. The equivalent to survival in this analysis is the time to 
Medwatch safety alert. 
The analysis has been extended outside of its usual application to an unconventional type of 
data. Several modifications to the original intent and the usual use were implemented.  
The analysis was performed using MedCalc software: Version 12.4.0 - Last modified: January 
2, 2013, © 1993-2013 MedCalc Software bvba, MedCalc Software, Acacialaan 22, B-8400 
Ostend, Belgium. http://www.medcalc.org/  
        
 
4 RESULTS  
4.1 Predictability of serious adverse reaction alerts for monoclonal antibodies 
 
Until Dec-2009, inclusive, 36 mAb alerts 
were issued containing 61 terms; 32 were 
assessed as observed. Many reactions 
which were not observed could have been 
predicted: 3 alerts for immunologic 
reactions and another 9 arguably 
predictable based on antibody target. 
Therefore, 18 out of 61 alerts (29.5%) 
according to this extended classification 
remain unobserved and unpredictable. 
 
Figure 1: mAb alert predictability 
 
Many unobserved reactions could have been predicted, for example: 
 Immunogenicity and anti-drug antibodies (ADAs), but no hypersensitivity reactions, 
were detected in pre-approval trials for adalimumab, basiliximab and daclizumab. 
 Bevacizumab alert dated Ap2007 described cases of tracheoesophageal fistula. Very 
similar to gastrointestinal perforations described in initial label (Feb-2004) this is 
apparently a direct extension of bevacizumab’s mechanism of action i.e. binding to 
vascular endothelial growth factor (VEGF).  
On the other hand, some alerts were issued for reactions classified as observed, such as: 
 According to the initial Sep-1998 label: “HERCEPTIN administration can result in the 
development of ventricular dysfunction and congestive heart failure.” This was based 
on trials using other cardiotoxic drugs (anthracyclines), but post-approval trials 
strengthened the evidence; so Aug-2005 cardiotoxicity alert was classified observed. 
 Immunomodulation by TNF-α inhibitors lead to several alerts for increased rate of 
infections, in particular opportunistic infections including histoplasmosis and 
tuberculosis. Since an increased infection rate should dictate vigilance towards all 
infections, we classified these alerts as observed.  
 
        
4.2 Kaplan-Meier estimate of time to safety alerts 
Time to publication of safety alerts was assessed by means of Kaplan-Meier estimate. The 
time coverage was extended up to Sep-2013, inclusive. There were 75 alerts: 42 observed vs 
33 unobserved. Median time to alert (median survival) is somewhat shorter for observed alerts 
(labelled Y) with respect to unobserved (labelled N): with 41 and 45 months, respectively The 
mean time to survival is almost the same: with 52.55 and 52.52 months, respectively (Chi-
square statistic gives a value of 0.001131. The statistical difference using logrank test is non-
significant with a P = 0.9732 The absence of statistical difference is demonstrated by the 
graphical representation of the curves which are almost super-imposable (see Figure 2).   
 
Figure 2: Kaplan-Meier survival curve of time to Medwatch safety alert 
 
0 50 100 150 200
0
20
40
60
80
100
Time (months)
S
ur
vi
va
l p
ro
ba
bi
lit
y 
(%
)
Group
N 
Y
 
Legend: Observed alerts (labelled Y); Unobserved alerts (labelled N); 
 
Even if not demonstrable by overall statistics over the entire period covered, the graph shows 
that there is a slight tendency of earlier reporting of observed alerts. Similarly to median 
values, the mean (SD) times to alert were also slightly shorter for observed alerts with respect 
to unobserved: 46.9 (39.6) and 51.2 (32.9) months, respectively. 
        
 
5 NEW SCIENTIFIC FINDINGS: 
 The findings in this work indicate that a certain level of prediction of ADRs is possible 
based on pre-marketing clinical and non-clinical data. At the same time, there is 
apparently insufficient effort placed on risk prediction and mitigation during drug 
development. The effort of drug manufacturers is understandably focussed on 
demonstration of safety and efficacy overall. Patients at risk of developing ADRs are 
often excluded from development programs due to risk of liability, but in real-life they 
equally require treatment.  
 As demonstrated by the Kaplan-Meier analysis, risk management planning may lead to 
earlier detection of safety concerns. Time to detection of an important safety finding is 
of utmost importance to public health. Earlier detection of safety concerns leads to 
decreased morbidity, mortality due ADRs and hence a range of benefits to healthcare. 
At the same time, the application of Kaplan-Meier analysis has been extended to the 
field of risk management planning; a field in which it has not been traditionally used. 
 Predicting ADRs is particularly important in high-risk situations in which the expected 
benefit is also high. Rechallenge following an ADR is such an example in which the 
benefit may, or may not, justify the risk. Rechallenge is of importance in all 
pharmacotherapy and therapeutic risk management. However, in immunological 
ADRs to biopharmaceuticals, rechallenge has particular risk-predictive features. It is 
proposed that each significant adverse reaction potentially leading to treatment 
discontinuation should have a reaction-specific rechallenge algorithm. 
 
Before attempting rechallenge the treating physician must consider the following (Figure 3): 
        
Figure 3: Points to consider in clinical decision making in the setting of intentional 
rechallenge 
Benefit
assessment
• Confirm real need of the causative (or suspect) drug
• Assess benefit-risk of alternative treatment or no medical treatment
• Define the acceptable level of risk justified by the expected benefit
Risk
assessment
• Evaluate the initial reaction and pathogenesis
• Estimate the risk upon rechallenge
• Identify predictive tests (pharmacogenetic, skin tests, anti-drug antibodies, etc)
Risk 
mitigation
• Identify prophylaxis or other risk minimization measures
• Ensure monitoring and access to facilities for early diagnosis and treatment
• Rechallenge under controlled conditions (e.g. hospitalisation)
Information 
and consent
•Provide information on benefit/risk of the causative drug and alternative treatment
•Obtain appropriate approval and patient consent
•Educate patients and families about early symptoms
 
        
 
6 CONCLUSIONS 
As in all pharmacotherapy and medical interventions in general, the expected benefits must 
outweigh the expected risk. Risk management for biopharmaceuticals is achieved by two 
principal means. The first step is risk estimation or prediction. This includes the measures 
taken to reliably assess risk factors of immunogenicity in a particular patient. The second step 
is risk mitigation, which covers the measures taken to decrease the risk to the minimum.  
Pharmacogenomics showed success in estimating the likelihood of adverse reactions to 
several small molecule drugs. Several immunogenicity assessment tests have been evaluated, 
but better predictive factors still need to be established for biopharmaceuticals.  
Risk of an ADR is particularly high when an ADR (or suspected ADR) has already occurred 
and the treatment should be resumed. Patients and populations at risk should be identified as 
part of risk-management planning. For biopharmaceuticals more than for other drugs, 
rechallenge following ADRs is a major challenge. The set of predictive methods should be 
particularly elaborate for such situations. A detailed algorithm for assessment of immune 
response tailored to each individual biopharmaceutical should describe the conditions under 
which benefit outweighs the risk. 
Developmental (pre-registrational) as well as established post-marketing risk management 
and minimisation action plans should routinely address both predictive methods and 
mitigation of consequences of biopharmaceutical immunogenicity starting from early 
development. The assay battery used in pre marketing should form a package with the drug; 
therefore.  This is in accordance with the current requirement in which an RMP is approved 
along with a drug.   
Risk management plans are now provided as open access to the public, including prescribers, 
pharmacists and patients. However, RMPs are still a document applicable primarily to the 
industry and regulators, and have not truly entered clinical/pharmacy practice. Early 
identification of risk on individual patient level is relevant at the individual’s, as well as on 
the global level. Involvement of patients in their own healthcare is growing. They are key 
stakeholders contributing to safety and, last but not least, pharmacoeconomics of early 
identification of risks. 
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